Full Press Release Details
Calliditas Year-end report, January - December 2023
Calliditas Therapeutics AB (Nasdaq Stockholm: CALTX)
2023: Full approval for TARPEYO in the US; a year of successes
OCTOBER - DECEMBER 2023
(COMPARED TO OCTOBER - DECEMBER 2022)
JANUARY - DECEMBER 2023
(COMPARED TO JANUARY -DECEMBER 2022)
"In December we were granted full approval by the FDA
for TARPEYO - a crowning achievement after many years of striving to bring an approved disease modifying treatment to patients with
CEO Ren e Aguiar-Lucander
KEY TAKEAWAYS FROM Q4, 2023
EXPECTED KEY EVENTS UPCOMING 6 MONTHS
Calliditas expects continued revenue growth:
Total net sales are estimated to be USD 150-180 million for the year
ending December 31, 2024
INVESTOR PRESENTATION
February 21, 2024, 14:30 CET
To participate via conference call register via this link: https://conference.financialhearings.com/teleconference/?id=50046870
For further information, please contact:
sa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com
The information in the press release is information
that Calliditas is obliged to make public pursuant to the EU Market Abuse Regulation. The information was sent for publication, through
the agency of the contact person set out above, on February 21, 2024, at 07:00 a.m. CET.
Calliditas Therapeutics is a biopharma company headquartered in Stockholm,
Sweden, focused on identifying, developing, and commercializing novel treatments in orphan indications with significant unmet medical
needs. Calliditas' common shares are listed on Nasdaq Stockholm (ticker: CALTX) and its American Depositary Shares are listed on
the Nasdaq Global Select Market (ticker: CALT). Visit Calliditas.com for further information.
Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the
development of Calliditas' pipeline. The words "may," "will," "could,"
"would," "should," "expect," "plan," "anticipate," "intend,"
"believe," "estimate," "predict," "project," "potential,"
"continue," "target," and similar expressions are intended to identify forward-looking statements, although
not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based
on management's current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors
that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements
contained in this press release, including, without limitation, any related to Calliditas' business, operations, clinical
trials, intellectual property of the NEFECON franchise globally, competition from other companies, pipeline development, revenue and
product sales projections or forecasts, 2024 revenue guidance and other risks identified in the section entitled "Risk
Factors" in Calliditas' reports filed with the Securities and Exchange Commission. Calliditas cautions you not to place
undue reliance on any forward-looking statements, which speak only as of the date they are made. Calliditas disclaims any obligation
to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on
which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in
the forward-looking statements. Any forward-looking statements contained in this press release represent Calliditas' views
only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.